Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › B cell lymphoma

B cell lymphoma

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for B cell lymphoma

19 trials tracked for B cell lymphoma.

19Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 13 Phase 1 5 Other / NA 1
  1. Phase 2 Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia Completed
  2. Phase 2 Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma Completed
  3. Phase 2 Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma Completed
  4. Phase 2 High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas Completed
  5. Phase 2 BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia Completed
  6. Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma Completed
Show 13 more trials
  1. Phase 2 Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) Completed
  2. Phase 2 Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Completed
  3. Phase 2 Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma Completed
  4. Phase 2 A Study for Patients With Non-Hodgkin's Lymphomas Completed
  5. Phase 2 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Completed
  6. Phase 2 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Completed
  7. Phase 2 PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma Completed
  8. Phase 1 A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma Completed
  9. Phase 1 CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Completed
  10. Phase 1 A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma Completed
  11. Phase 1 Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies Completed
  12. Phase 1 Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma Completed
  13. N/A Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor Completed

Showing the 19 most-cited and recently-updated of 19 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
BTK inhibitors do not significantly increase second primary malignancy risk in B-cell lymphoma patients
Hematology Meta-analysis
BTK inhibitors do not significantly increase second primary malignancy risk in B-cell lymphoma patients BTK inhibitors do not appear to cause second primary cancers
This meta-analysis of 9337 patients found that BTK inhibitors do not significantly increase the risk of second primary malignancies compared…
New data suggests that a common class of drugs used to treat certain blood cancers does not increase the risk of developing new cancers.
Oct 1, 2026
Clinically significant CMV infection occurs in 9% of patients receiving bispecific antibodies for hematologic malignancies
Hematology Meta-analysis
Clinically significant CMV infection occurs in 9% of patients receiving bispecific antibodies for hematologic malignancies Bispecific Antibodies Linked to Lower Rates of CMV Infection
This meta-analysis of 23 studies and a single-center cohort evaluated bispecific antibody use in multiple myeloma, B-cell lymphoma, and acut…
New data shows that patients receiving bispecific antibodies for certain blood cancers may have lower rates of serious CMV infections.
Frontiers Aug 27, 2026